Mirum Pharmaceuticals Inc.
Rating
Updated: Sep 18, 2026Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMAR...
Latest News
6 days ago · seekingalpha.com
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptMirum Pharmaceuticals, Inc. (MIRM) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
6 days ago · seekingalpha.com
Mirum Pharmaceuticals: Oversold And Set To Rally On Critical Pipeline-Related EventsMirum Pharmaceuticals is approaching major catalysts, notably the FDA's PDUFA decision for zilurgisertib (Sept. 26) & pivotal Phase 3 data on its chronic hepatitis D drug, a potential blockbuster. MIRM's pipeline expansion and strategic acquisitions have delayed profitability to 2028, but management raised FY 2026 sales guidance to $680–$700 million. Strong commercial traction from LIVMARLI and bile acid products drove Q2 revenue above expectations, but operating losses widened due to R&D and integration costs.
12 days ago · seekingalpha.com
Mirum Pharmaceuticals, Inc. (MIRM) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptMirum Pharmaceuticals, Inc. (MIRM) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
14 days ago · businesswire.com
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical OfficerFOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer.
18 days ago · zacks.com
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report?Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
20 days ago · businesswire.com
Mirum Pharmaceuticals to Participate in Upcoming Investor ConferencesFOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences.
28 days ago · defenseworld.net
BlackRock Inc. Takes $513.95 Million Position in Mirum Pharmaceuticals, Inc. $MIRMBlackRock Inc. purchased a new stake in Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM) in the undefined quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 4,390,063 shares of the company's stock, valued at approximately $513,945,000. BlackRock Inc. owned about 7.20% of Mirum Pharmaceuticals at the end
2 months ago · zacks.com
Mirum's Q2 Earnings Lag Estimates, Revenues Beat, 2026 View RaisedMIRM Q2 earnings miss estimates while revenues beat the same, as Livmarli and bile acid drugs fuel growth, prompting a higher 2026 sales outlook.
2 months ago · seekingalpha.com
Mirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call TranscriptMirum Pharmaceuticals, Inc. (MIRM) Q2 2026 Earnings Call Transcript
2 months ago · marketbeat.com
Mirum Pharmaceuticals Q2 Earnings Call HighlightsMirum Pharmaceuticals NASDAQ: MIRM reported second-quarter net product sales of $176 million and raised its full-year 2026 product sales outlook to $680 million to $700 million, while outlining several upcoming clinical and regulatory milestones across its rare liver and rare genetic disease portfolios.
Analyst Summary
Add to Watchlist
Select watchlists to add or remove MIRM